Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 331

1.

Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.

Nowell SA, Ahn J, Rae JM, Scheys JO, Trovato A, Sweeney C, MacLeod SL, Kadlubar FF, Ambrosone CB.

Breast Cancer Res Treat. 2005 Jun;91(3):249-58.

2.

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.

Wegman P, Elingarami S, Carstensen J, Stål O, Nordenskjöld B, Wingren S.

Breast Cancer Res. 2007;9(1):R7.

3.

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA.

J Natl Cancer Inst. 2005 Jan 5;97(1):30-9.

PMID:
15632378
4.

Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.

Gaston C, Kolesar J.

Clin Adv Hematol Oncol. 2008 Nov;6(11):825-33.

PMID:
19194367
5.

Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy.

Kiyotani K, Mushiroda T, Sasa M, Bando Y, Sumitomo I, Hosono N, Kubo M, Nakamura Y, Zembutsu H.

Cancer Sci. 2008 May;99(5):995-9. doi: 10.1111/j.1349-7006.2008.00780.x.

6.

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.

Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN.

J Clin Oncol. 2005 Dec 20;23(36):9312-8.

PMID:
16361630
7.

Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.

Dezentjé VO, van Blijderveen NJ, Gelderblom H, Putter H, van Herk-Sukel MP, Casparie MK, Egberts AC, Nortier JW, Guchelaar HJ.

J Clin Oncol. 2010 May 10;28(14):2423-9. doi: 10.1200/JCO.2009.25.0894.

PMID:
20385997
8.

Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.

Damodaran SE, Pradhan SC, Umamaheswaran G, Kadambari D, Reddy KS, Adithan C.

Cancer Chemother Pharmacol. 2012 Jul;70(1):75-81. doi: 10.1007/s00280-012-1891-1.

PMID:
22623212
9.

Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.

Park IH, Ro J, Park S, Lim HS, Lee KS, Kang HS, Jung SY, Lee S.

Breast Cancer Res Treat. 2012 Jan;131(2):455-61. doi: 10.1007/s10549-011-1425-2.

PMID:
21437611
10.

Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy.

Nowell S, Sweeney C, Winters M, Stone A, Lang NP, Hutchins LF, Kadlubar FF, Ambrosone CB.

J Natl Cancer Inst. 2002 Nov 6;94(21):1635-40.

PMID:
12419790
11.

Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen.

Siegelmann-Danieli N, Kurnik D, Lomnicky Y, Vesterman-Landes J, Katzir I, Bialik M, Loebstein R.

Breast Cancer Res Treat. 2011 Jan;125(2):505-10. doi: 10.1007/s10549-010-1008-7.

PMID:
20593233
12.

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.

Wegman P, Vainikka L, Stål O, Nordenskjöld B, Skoog L, Rutqvist LE, Wingren S.

Breast Cancer Res. 2005;7(3):R284-90.

13.

Genotype-guided adjuvant endocrine therapy: new tricks from an old drug?

Peppercorn J, A Carey L.

Expert Rev Anticancer Ther. 2008 Feb;8(2):191-4. doi: 10.1586/14737140.8.2.191.

PMID:
18279059
14.

The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users.

Bijl MJ, van Schaik RH, Lammers LA, Hofman A, Vulto AG, van Gelder T, Stricker BH, Visser LE.

Breast Cancer Res Treat. 2009 Nov;118(1):125-30. doi: 10.1007/s10549-008-0272-2.

PMID:
19189212
15.

No association between CYP2D6*10 genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment.

Toyama T, Yamashita H, Sugiura H, Kondo N, Iwase H, Fujii Y.

Jpn J Clin Oncol. 2009 Oct;39(10):651-6. doi: 10.1093/jjco/hyp076.

PMID:
19596663
16.

Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?

Higgins MJ, Rae JM, Flockhart DA, Hayes DF, Stearns V.

J Natl Compr Canc Netw. 2009 Feb;7(2):203-13. Review.

PMID:
19200418
17.

Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy.

Thompson AM, Johnson A, Quinlan P, Hillman G, Fontecha M, Bray SE, Purdie CA, Jordan LB, Ferraldeschi R, Latif A, Hadfield KD, Clarke RB, Ashcroft L, Evans DG, Howell A, Nikoloff M, Lawrence J, Newman WG.

Breast Cancer Res Treat. 2011 Jan;125(1):279-87. doi: 10.1007/s10549-010-1139-x.

PMID:
20809362
18.

Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy.

Grabinski JL, Smith LS, Chisholm GB, Drengler R, Rodriguez GI, Lang AS, Kalter SP, Garner AM, Fichtel LM, Hollsten J, Pollock BH, Kuhn JG.

Breast Cancer Res Treat. 2006 Jan;95(1):13-6.

PMID:
16317586
19.

Impaired tamoxifen metabolism reduces survival in familial breast cancer patients.

Newman WG, Hadfield KD, Latif A, Roberts SA, Shenton A, McHague C, Lalloo F, Howell S, Evans DG.

Clin Cancer Res. 2008 Sep 15;14(18):5913-8. doi: 10.1158/1078-0432.CCR-07-5235.

20.

Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors.

Ahern TP, Christensen M, Cronin-Fenton DP, Lunetta KL, Søiland H, Gjerde J, Garne JP, Rosenberg CL, Silliman RA, Sørensen HT, Lash TL, Hamilton-Dutoit S.

Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1937-43. doi: 10.1158/1055-9965.EPI-11-0419.

Supplemental Content

Support Center